Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Sign Up to like & getrecommendations! Published in 2022 at "Arquivos de Neuro-Psiquiatria"
DOI: 10.1590/0004-282x-anp-2022-s129
Abstract: ABSTRACT Background:  Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. Immunotherapies, particularly immune checkpoint inhibitors (ICPi), have revolutionized cancer treatment, but their role in glioblastoma is uncertain.… read more here.
Keywords: glioblastoma; checkpoint inhibitors; immune checkpoint; glioblastoma learned ... See more keywords